MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
5.23
+0.08
+1.55%
After Hours: 5.07 -0.16 -3.06% 16:21 03/23 EDT
OPEN
5.33
PREV CLOSE
5.15
HIGH
5.36
LOW
5.08
VOLUME
2.14M
TURNOVER
0
52 WEEK HIGH
43.12
52 WEEK LOW
4.020
MARKET CAP
513.39M
P/E (TTM)
-1.7974
1D
5D
1M
3M
1Y
5Y
Fate Therapeutics: If You Are Comparing With Geron, Do It Thoroughly
Seeking Alpha · 1h ago
Biotech ETF XBI drops to an 8-month low
Seeking Alpha · 23h ago
Vanguard Group Now Owns 10.12% of Fate Therapeutics (FATE)
NASDAQ · 03/10 21:42
Analysts Conflicted on These Healthcare Names: Natera (NTRA), Mersana Therapeutics (MRSN) and Fate Therapeutics (FATE)
TipRanks · 03/03 05:30
Citigroup Maintains Buy on Fate Therapeutics, Raises Price Target to $10
Benzinga · 03/02 12:24
Citigroup Adjusts Fate Therapeutics Price Target to $10 From $9, Maintains Buy Rating
Citigroup Adjusts Fate Therapeutics Price Target to $10 From $9, Maintains Buy Rating
MT Newswires · 03/02 08:12
Expert Ratings for Fate Therapeutics
Benzinga · 03/01 20:01
Analysts Are Bullish on These Healthcare Stocks: Masimo (MASI), Fate Therapeutics (FATE)
TipRanks · 03/01 12:30
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer. It uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The Company's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.